A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Prophylactic measures such as vancomycin, povidone-iodine and saline irrigation yielded similar rates of periprosthetic joint infection and wound complications at 3 months for high-risk patients ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

In the case described in the Equine Veterinary Education Journal, x-rays and hoof testers were not able to predict the location of a subsolar abscess in this horse's foot ...

The cause of most concern are seed oils - a type of vegetable oil derived from plant seeds but the cause of most concern are ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Learn 6 facts about mastitis, from recognizing early symptoms to effective treatments, helping breastfeeding parents prevent ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...